Efficacy of the tubercidin antileishmania action associated with an inhibitor of the nucleoside transport.
Tubercidin (TUB) is an adenosine analog with potent antiparasite action, unfortunately associated with severe host toxicity. Prevention of TUB toxicity can be reached associating nitrobenzylthioinosine (NBMPR), an inhibitor of the purine nucleoside transport, specifically target to the mammal cells. It was demonstrated that this nucleoside transport inhibitor has no significant effect in the in vitro uptake of TUB by Schistosoma mansoni and Trypanosoma gambiense. Seeking to evaluate if the association of these compounds is also effective against leishmania, we analyzed the TUB-NBMPR combined treatment in in vitro cultures of promastigote forms of Leishmania (L.) amazonensis, Leishmania (L.) chagasi, Leishmania (L.) major, and Leishmania (V.) braziliensis as well as in cultures of amastigote forms of L. (L.) amazonensis, mice macrophages infected with L. (L.) amazonensis, and in vivo tests in BALB/c mice infected with L. (L.) amazonensis. We demonstrated that TUB-NBMPR combined treatment can be effective against leishmania cells protecting mammalian cells from TUB toxicity.
Aoki
J I
JI
Dept. Moléstias Infecciosas e Parasitárias, Instituto de Medicina Tropical, Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 4704 degrees andar, São Paulo, SP 05403-000, Brazil.
Yamashiro-Kanashiro
E H
EH
Ramos
D C C
DC
Cotrim
P C
PC
D000818:Animals; D000977:Antiparasitic Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D002478:Cells, Cultured; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007891:Leishmania / Q000187:drug effects*; D007896:Leishmaniasis / Q000188:drug therapy*; D008264:Macrophages / Q000187:drug effects / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D012550:Schistosoma mansoni / Q000187:drug effects; D013868:Thioinosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013873:Thionucleotides / Q000494:pharmacology / Q000627:therapeutic use*; D014347:Trypanosoma brucei gambiense / Q000187:drug effects; D014372:Tubercidin / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity
D000977:Antiparasitic Agents; D004791:Enzyme Inhibitors; D013873:Thionucleotides; D013868:Thioinosine; C028318:nitrobenzylthioinosine 5'-monophosphate; D014372:Tubercidin
Antimicrob Agents Chemother. 1983 Aug;24(2):233-6
6638989
Pharmacol Ther. 2003 Sep;99(3):283-309
12951162
Infect Immun. 1993 May;61(5):2131-7
7683002
Eukaryot Cell. 2004 Apr;3(2):245-54
15075255
Acta Trop. 1982 Sep;39(3):219-24
6128890
J Commun Dis. 2000 Dec;32(4):289-94
11668940
Biochem Pharmacol. 1987 Nov 15;36(22):3815-21
3689423
Int J Pharm. 2000 Mar 10;196(2):253-6
10699730
Proc Natl Acad Sci U S A. 1983 Nov;80(21):6667-70
6579551
Lancet. 2005 Oct 29-Nov 4;366(9496):1561-77
16257344
Exp Parasitol. 1991 Oct;73(3):369-75
1915751
Biochem Pharmacol. 1991 Mar 1;41(5):815-20
1900158
Antimicrob Agents Chemother. 2003 Jun;47(6):1895-901
12760864
Mol Biochem Parasitol. 1984 Nov;13(3):243-61
6396514
Nucleic Acids Res. 1990 Nov 11;18(21):6399-408
2243782
Parasitol Today. 1993 Sep;9(9):323-8
15463794
J Infect. 2005 Aug;51(2):157-64
16038768
Trends Parasitol. 2003 Nov;19(11):502-8
14580961
Parasitol Today. 2000 Jul;16(7):292-7
10858648